Escherichia coli in the production of biopharmaceuticals.
E. coli
biopharmaceuticals
recombinant DNA technology
recombinant proteins
Journal
Biotechnology and applied biochemistry
ISSN: 1470-8744
Titre abrégé: Biotechnol Appl Biochem
Pays: United States
ID NLM: 8609465
Informations de publication
Date de publication:
08 Sep 2024
08 Sep 2024
Historique:
received:
23
04
2024
accepted:
23
08
2024
medline:
9
9
2024
pubmed:
9
9
2024
entrez:
9
9
2024
Statut:
aheadofprint
Résumé
Escherichia coli has shouldered a massive workload with the discovery of recombinant DNA technology. A new era began in the biopharmaceutical industry with the production of insulin, the first recombinant protein, in E. coli and its use in treating diabetes. After insulin, many biopharmaceuticals produced from E. coli have been approved by the US Food and Drug Administration and the European Medicines Agency to treat various human diseases. Although E. coli has some disadvantages, such as lack of post-translational modifications and toxicity, it is an important host with advantages such as being a well-known bacterium in recombinant protein production, cheap, simple production system, and high yield. This study examined biopharmaceuticals produced and approved in E. coli under the headings of peptides, hormones, enzymes, fusion proteins, antibody fragments, vaccines, and other pharmaceuticals. The topics on which these biopharmaceuticals were approved for treating human diseases, when and by which company they were produced, and their use and development in the field are included.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Author(s). Biotechnology and Applied Biochemistry published by Wiley Periodicals LLC on behalf of International Union of Biochemistry and Molecular Biology.
Références
Williams DC, Van Frank RM, Muth WL, Burnett JP. Cytoplasmic inclusion bodies in Escherichia coli producing biosynthetic human insulin proteins. Science. 1982;215:687–689.
Quianzon CC, Cheikh I. History of insulin. J Community Hosp Intern Med Perspect. 2012;2.
Gupta V, Sengupta M, Prakash J, Tripathy BC, Gupta V, Sengupta M, et al. Production of recombinant pharmaceutical proteins. Basic Appl Aspects Biotechnol. 2017:77–101.
Baeshen MN, Al‐Hejin AM, Bora RS, Ahmed MM, Ramadan HA, Saini KS, et al. Production of biopharmaceuticals in E. coli: current scenario and future perspectives. J Microbiol Biotechnol. 2015;25:953‒962.
Tripathi NK, Shrivastava A. Recent developments in bioprocessing of recombinant proteins: expression hosts and process development. Front Bioeng Biotechnol. 2019;7:420.
Eczacioglu N, Ulusu Y, Gokce İ, Lakey JH. Investigation of mutations (L41F, F17M, N57E, Y99F_Y134W) effects on the TolAIII‐UnaG fluorescence protein's unconjugated bilirubin (UC‐BR) binding ability and thermal stability properties. Prep Biochem Biotechnol. 2022;52:365–374.
İncir İ, Kaplan Ö, Bilgin S, Gökçe İ. Development of a fluorescent protein based FRET biosensor for determination of protease activity. Sakarya Univ J Sci. 2021;25:1235–1244.
Kaplan Ö, Gök MK, Pekmez M, Erden Tayhan S, Özgümüş S, Gökçe İ, et al. Development of recombinant protein‐based nanoparticle systems for inducing tumor cell apoptosis: in vitro evaluation of their cytotoxic and apoptotic effects on cancer cells. J Drug Delivery Sci Technol. 2024;95:105565.
İncir İ, Kaplan Ö. Escherichia coli as a versatile cell factory: advances and challenges in recombinant protein production. Protein Expression Purif. 2024;219:106463.
Mital S, Christie G, Dikicioglu D. Recombinant expression of insoluble enzymes in Escherichia coli: a systematic review of experimental design and its manufacturing implications. Microb Cell Fact. 2021;20:208.
Dubey KK, Kumar A, Baldia A, Rajput D, Kateriya S, Singh R, et al. Biomanufacturing of glycosylated antibodies: challenges, solutions, and future prospects. Biotechnol Adv. 2023;69:108267.
Niazi SK, Magoola M. Advances in Escherichia coli‐based therapeutic protein expression: mammalian conversion, continuous manufacturing, and cell‐free production. Biologics. 2023;3:380–401.
Johnson IS. Human insulin from recombinant DNA technology. Science. 1983;219:632–637.
Jozala AF, Geraldes DC, Tundisi LL, Feitosa VA, Breyer CA, Cardoso SL, et al. Biopharmaceuticals from microorganisms: from production to purification. Braz J Microbiol. 2016;47:51–63.
FDA. LYUMJEV (insulin lispro‐aabc) injection, for subcutaneous or intravenous use. 2020. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761109s003lbl.pdf. Accessed 3 Oct 2023.
EMA. Lyumjev. 2020. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/lyumjev‐previously‐liumjev. Accessed 3 Oct 2023.
FDA. SOGROYA® (somapacitan‐beco) injection, for subcutaneous use Initial U.S. 2020. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761156s005lbl.pdf. Accessed 3 Oct 2023.
EMA. Sogroya. 2021. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/sogroya. Accessed 3 Oct 2023.
Johannsson G, Gordon MB, Højby Rasmussen M, Håkonsson IH, Karges W, Sværke C, et al. Once‐weekly somapacitan is effective and well tolerated in adults with GH deficiency: a randomized phase 3 trial. J Clin Endocrinol Metab. 2020;105:e1358–e1376.
Miller BS, Blair JC, Rasmussen MH, Maniatis A, Kildemoes RJ, Mori J, et al. Weekly somapacitan is effective and well tolerated in children with GH deficiency: the randomized phase 3 REAL4 trial. J Clin Endocrinol Metab. 2022;107:3378–3388.
FDA. SKYTROFA™ (lonapegsomatropin‐tcgd) for injection, for subcutaneous use. 2021. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761177lbl.pdf
Sanchez‐Garcia L, Martín L, Mangues R, Ferrer‐Miralles N, Vázquez E, Villaverde A. Recombinant pharmaceuticals from microbial cells: a 2015 update. Microb Cell Fact. 2016;15:1–7.
FDA. INTRON® A. 2018. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103132Orig1s5199lbl.pdf. Accessed 3 Oct 2023.
FDA. BESREMi (ropeginterferon alfa‐2b‐njft) injection, for subcutaneous use. 2021. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761166s000lbl.pdf. Accessed 3 Oct 2023.
Gisslinger H, Klade C, Georgiev P, Krochmalczyk D, Gercheva‐Kyuchukova L, Egyed M, et al. Ropeginterferon alfa‐2b versus standard therapy for polycythaemia vera (PROUD‐PV and CONTINUATION‐PV): a randomised, non‐inferiority, phase 3 trial and its extension study. Lancet Haematol. 2020;7:e196–e208.
Okikiolu J, Woodley C, Cadman‐Davies L, O'Sullivan J, Radia D, Garcia NC, et al. Real world experience with ropeginterferon alpha‐2b (Besremi) in essential thrombocythaemia and polycythaemia vera following exposure to pegylated interferon alfa‐2a (Pegasys). Leuk Res Rep. 2023;19:100360.
Bang S‐Y, Lee S‐E. A case report of ropeginterferon alfa‐2b for polycythemia vera during pregnancy. Hematol Rep. 2023;15:172–179.
EMA. Forsteo. 2003. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/forsteo. Accessed 3 Oct 2023.
EMA. Sondelbay. 2022. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/sondelbay‐0. Accessed 3 Oct 2023.
Kim ES, Keating GM. Recombinant human parathyroid hormone (1–84): a review in hypoparathyroidism. Drugs. 2015;75:1293–1303.
Mannstadt M, Clarke BL, Bilezikian JP, Bone H, Denham D, Levine MA, et al. Safety and efficacy of 5 years of treatment with recombinant human parathyroid hormone in adults with hypoparathyroidism. J Clin Endocrinol Metab. 2019;104:5136–5147.
Marcucci G, Beccuti G, Carosi G, Cetani F, Cianferotti L, Colao AM, et al. Multicenter retro‐prospective observational study on chronic hypoparathyroidism and rhPTH (1–84) treatment. J Endocrinol Invest. 2022;45:1653–1662.
EMA. Natpar. 2017. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/natpar. Accessed 3 Oct 2023.
Silva AC, Costa CP, Almeida H, Moreira JN, Sousa Lobo JM. Hormones, blood products, and therapeutic enzymes. Adv Biochem Eng Biotechnol. 2020;171:115–153.
Botson JK, Saag K, Peterson J, Parikh N, Ong S, La D, et al. A Randomized, placebo‐controlled study of methotrexate to increase response rates in patients with uncontrolled gout receiving pegloticase: primary efficacy and safety findings. Arthritis Rheumatol. 2023;75:293–304.
Cook K, Adamski K, Gomes A, Tuttle E, Kalden H, Cochran E, et al. Effects of metreleptin on patient outcomes and quality of life in generalized and partial lipodystrophy. J Endocrine Soc. 2021;5:bvab019.
FDA. VORAXAZE® (glucarpidase) for injection, for intravenous use. 2012. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125327lbl.pdf. Accessed 3 Oct 2023.
EMA. Voraxaze. 2022. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/voraxaze‐0. Accessed 3 Oct 2023.
McElwain L, Phair K, Kealey C, Brady D. Current trends in biopharmaceuticals production in Escherichia coli. Biotechnol Lett. 2022;44:917–931.
Angiolillo AL, Schore RJ, Devidas M, Borowitz MJ, Carroll AJ, Gastier‐Foster JM, et al. Pharmacokinetic and pharmacodynamic properties of calaspargase pegol Escherichia coli L‐asparaginase in the treatment of patients with acute lymphoblastic leukemia: results from Children's Oncology Group Study AALL07P4. J Clin Oncol. 2014;32:3874.
FDA. PALYNZIQ (pegvaliase‐pqpz) injection, for subcutaneous use. 2018. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761079s000lbl.pdf. Accessed 3 Oct 2023.
Adams D, Andersson HC, Bausell H, Crivelly K, Eggerding C, Lah M, et al. Use of pegvaliase in the management of phenylketonuria: case series of early experience in US clinics. Mol Genet Metab Rep. 2021;28:100790.
Lah M, Cook K, Gomes DA, Liu S, Tabatabaeepour N, Kirson N, et al. Real‐world treatment, dosing, and discontinuation patterns among patients treated with pegvaliase for phenylketonuria: evidence from dispensing data. Mol Genet Metab Rep. 2022;33:100918.
FDA. REVCOVI (elapegademase‐lvlr) injection, for intramuscular use. 2018. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761092s000lbl.pdf. Accessed 3 Oct 2023.
Dorsey MJ, Rubinstein A, Lehman H, Fausnight T, Wiley JM, Haddad E. PEGylated recombinant adenosine deaminase maintains detoxification and lymphocyte counts in patients with ADA‐SCID. J Clin Immunol. 2023;43:951–964.
Murguia‐Favela L, Suresh S, Wright NAM, Alvi S, Tehseen S, Hernandez‐Trujillo V, et al. Long‐term immune reconstitution in ADA‐deficient patients treated with elapegademase: a real‐world experience. Allergy Clin Immunol Prac. 2023;11:1725–1733.
de la Fuente M, Lombardero L, Gómez‐González A, Solari C, Angulo‐Barturen I, Acera A, et al. Enzyme therapy: current challenges and future perspectives. Int J Mol Sci. 2021;22:9181.
FDA. NATRECOR® (nesiritide) lyophilized powder for intravenous use. 2001. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020920s031lbl.pdf. Accessed 3 Oct 2023.
Ajingi YS, Rukying N, Aroonsri A, Jongruja N. Recombinant active peptides and their therapeutic functions. Curr Pharm Biotechnol. 2022;23:645–663.
Gierach I, Galiardi JM, Marshall B, Wood DW, Chapter 26—protein drug production and formulation. In: Adejare A, editor. Remington. 23rd ed. Academic Press; 2021. p. 489–547.
Wang L, Wang N, Zhang W, Cheng X, Yan Z, Shao G, et al. Therapeutic peptides: current applications and future directions. Signal Transd Targeted Therapy. 2022;7:48.
EMA. Voxzogo. 2021. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/voxzogo. Accessed 3 Oct 2023.
FDA. VOXZOGO (vosoritide) for injection, for subcutaneous use. 2021. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214938s000lbl.pdf. Accessed 3 Oct 2023.
Savarirayan R, Tofts L, Irving M, Wilcox W, Bacino CA, Hoover‐Fong J, et al. Once‐daily, subcutaneous vosoritide therapy in children with achondroplasia: a randomised, double‐blind, phase 3, placebo‐controlled, multicentre trial. Lancet North Am Ed. 2020;396:684–692.
Savarirayan R, Tofts L, Irving M, Wilcox WR, Bacino CA, Hoover‐Fong J, et al. Safe and persistent growth‐promoting effects of vosoritide in children with achondroplasia: 2‐year results from an open‐label, phase 3 extension study. Genet Med. 2021;23:2443–2447.
EMA. Oxervate. 2017. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/oxervate. Accessed 3 Oct 2023.
FDA. OXERVATE™ (cenegermin‐bkbj) ophthalmic solution for topical ophthalmic use. 2018. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761202s000lbl.pdf. Accessed 3 Oct 2023.
Arboleda A, Ta CN. Observational study of cenegermin for the treatment of limbal stem cell deficiency associated with neurotrophic keratopathy. Therap Adv Ophthalmol. 2022;14:25158414221134598.
White CA, Affeldt J. Topical cenegermin associated ocular surface and contact lens drug precipitate deposit formation. Am J Ophthalmol Case Rep. 2022;27:101584.
EMA. Idefirix. 2020. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/idefirix. Accessed 3 Oct 2023.
Couzi L, Malvezzi P, Amrouche L, Anglicheau D, Blancho G, Caillard S, et al. Imlifidase for kidney transplantation of highly sensitized patients with a positive crossmatch: the French Consensus Guidelines. Transpl Int. 2023;36:11244.
Huang E, Maldonado AQ, Kjellman C, Jordan SC. Imlifidase for the treatment of anti‐HLA antibody‐mediated processes in kidney transplantation. Am J Transplant. 2022;22:691–697.
Li SW, Zhang J, Li YM, Ou SH, Huang GY, He ZQ, et al. A bacterially expressed particulate hepatitis E vaccine: antigenicity, immunogenicity and protectivity on primates. Vaccine. 2005;23:2893–2901.
Zhu F‐C, Zhang J, Zhang X‐F, Zhou C, Wang Z‐Z, Huang S‐J, et al. Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large‐scale, randomised, double‐blind placebo‐controlled, phase 3 trial. Lancet North Am Ed. 2010;376:895–902.
Zhao F‐H, Wu T, Hu Y‐M, Wei L‐H, Li M‐Q, Huang W‐J, et al. Efficacy, safety, and immunogenicity of an Escherichia coli‐produced Human Papillomavirus (16 and 18) L1 virus‐like‐particle vaccine: end‐of‐study analysis of a phase 3, double‐blind, randomised, controlled trial. Lancet Infect Dis. 2022;22:1756–1768.
EMA. Strangvac. 2021. Available from: https://www.ema.europa.eu/en/medicines/veterinary/EPAR/strangvac. Accessed 3 Oct 2023.
Robinson C, Waller AS, Frykberg L, Flock M, Zachrisson O, Guss B, et al. Intramuscular vaccination with Strangvac is safe and induces protection against equine strangles caused by Streptococcus equi. Vaccine. 2020;38:4861–4868.
Zhu J. Mammalian cell protein expression for biopharmaceutical production. Biotechnol Adv. 2012;30:1158–1170.
Harding CM, Nasr MA, Scott NE, Goyette‐Desjardins G, Nothaft H, Mayer AE, et al. A platform for glycoengineering a polyvalent pneumococcal bioconjugate vaccine using E. coli as a host. Nat Commun. 2019;10:891.
Herbert JA, Kay EJ, Faustini SE, Richter A, Abouelhadid S, Cuccui J, et al. Production and efficacy of a low‐cost recombinant pneumococcal protein polysaccharide conjugate vaccine. Vaccine. 2018;36:3809–3819.
Kay EJ, Mauri M, Willcocks SJ, Scott TA, Cuccui J, Wren BW. Engineering a suite of E. coli strains for enhanced expression of bacterial polysaccharides and glycoconjugate vaccines. Microb Cell Fact. 2022;21:66.
Wang X, Cohn A, Comanducci M, Andrew L, Zhao X, MacNeil JR, et al. Prevalence and genetic diversity of candidate vaccine antigens among invasive Neisseria meningitidis isolates in the United States. Vaccine. 2011;29:4739–4744.
FDA. TRUMENBA® (Meningococcal Group B Vaccine) Suspension for intramuscular injection. 2014. Available from: https://www.fda.gov/media/89936/download. Accessed 3 Oct 2023.
EMA. Trumenba. 2017. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/trumenba. Accessed 3 Oct 2023.
Drazan D, Czajka H, Maguire JD, Pregaldien J‐L, Maansson R, O'Neill R, et al. A phase 3 study to assess the immunogenicity, safety, and tolerability of MenB‐FHbp administered as a 2‐dose schedule in adolescents and young adults. Vaccine. 2022;40:351–358.
Stefanizzi P, Bianchi FP, Martinelli A, Di Lorenzo A, De Petro P, Graziano G, et al. Safety profile of MenB‐FHBp vaccine among adolescents: data from surveillance of Adverse Events Following Immunization in Puglia (Italy), 2018–2020. Hum Vaccin Immunother. 2022;18:2041359.
EMA. Bexsero. 2013. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/bexsero. Accessed 3 Oct 2023.
FDA. BEXSERO (Meningococcal Group B Vaccine) suspension, for intramuscular injection. 2015. Available from: https://www.fda.gov/media/90996/download. Accessed 3 Oct 2023.
Perez‐Vilar S, Dores GM, Marquez PL, Ng CS, Cano MV, Rastogi A, et al. Safety surveillance of meningococcal group B vaccine (Bexsero®), Vaccine Adverse Event Reporting System, 2015–2018. Vaccine. 2022;40:247–254.
Marshall GS, Abbing‐Karahagopian V, Marshall HS, Cenci S, Conway JH, Occhipinti E, et al. A comprehensive review of clinical and real‐world safety data for the four‐component serogroup B meningococcal vaccine (4CMenB). Expert Rev Vaccines. 2023;22:530–544.
Castilla J, García Cenoz M, Abad R, Sánchez‐Cambronero L, Lorusso N, Izquierdo C, et al. Effectiveness of a meningococcal group B vaccine (4CMenB) in children. N Engl J Med. 2023;388:427–438.
Shabani SH, Zakeri S, Mortazavi Y, Mehrizi AA. Immunological evaluation of two novel engineered Plasmodium vivax circumsporozoite proteins formulated with different human‐compatible vaccine adjuvants in C57BL/6 mice. Med Microbiol Immunol. 2019;208:731–745.
Marciani DJ, Kensil CR, Beltz GA, Hung C‐H Cronier J, Aubert A. Genetically‐engineered subunit vaccine against feline leukaemia virus: protective immune response in cats. Vaccine. 1991;9:89–96.
EMA. Leucogen. 2009. Available from: https://www.ema.europa.eu/en/medicines/veterinary/EPAR/leucogen. Accessed 3 Oct 2023.
EMA. Letifend. 2016. Available from: https://www.ema.europa.eu/en/medicines/veterinary/EPAR/letifend. Accessed 3 Oct 2023.
Hajdusek O, Perner J. VLA15, a new global Lyme disease vaccine undergoes clinical trials. Lancet Infect Dis. 2023;23:1105–1106.
Narayanan R, Kuppermann BD, Jones C, Kirkpatrick P Ranibizumab. Nat Rev Drug Discovery. 2006;5:815–816.
Mordenti J, Cuthbertson RA, Ferrara N, Thomsen K, Berleau L, Licko V, et al. Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I‐labeled full‐length and Fab antibodies in rhesus monkeys following intravitreal administration. Toxicol Pathol. 1999;27:536–544.
Stewart MW. A review of ranibizumab for the treatment of diabetic retinopathy. Ophthalmol Ther. 2017;6:33–47.
FDA. BYOOVIZ (ranibizumab‐nuna) injection, for intravitreal use. 2021. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761202s000lbl.pdf. Accessed 3 Oct 2023.
FDA. SUSVIMO™ (ranibizumab injection) for intravitreal use via SUSVIMO ocular implant. 2021. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761197s000lbl.pdf. Accessed 3 Oct 2023.
Ross JS, Gray K, Gray GS, Worland PJ, Rolfe M. Anticancer antibodies. Am J Clin Pathol. 2003;119:472–485.
Ahmadzadeh M, Farshdari F, Nematollahi L, Behdani M, Mohit E. Anti‐HER2 scFv expression in Escherichia coli SHuffle® T7 express cells: effects on solubility and biological activity. Mol Biotechnol. 2020;62:18–30.
Koçer İ, Cox EC, DeLisa MP, Çelik E. Effects of variable domain orientation on anti‐HER2 single‐chain variable fragment antibody expressed in the Escherichia coli cytoplasm. Biotechnol Progr. 2021;37:e3102.
Peng Y, Wu Z, Pang Z, Zhang L, Song D, Liu F, et al. Manufacture and evaluation of a HER2‐positive breast cancer immunotoxin 4D5Fv‐PE25. Microb Cell Fact. 2023;22:100.
Nesbitt A, Fossati G, Bergin M, Stephens P, Stephens S, Foulkes R, et al. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti‐tumor necrosis factor α agents. Inflamm Bowel Dis. 2007;13:1323–1332.
Hutterer KM, Zhang Z, Michaels ML, Belouski E, Hong RW, Shah B, et al. Targeted codon optimization improves translational fidelity for an Fc fusion protein. Biotechnol Bioeng. 2012;109:2770–2777.
Shimamoto G, Gegg C, Boone T, Queva C. Peptibodies: a flexible alternative format to antibodies. MAbs. 2012;4:586–591.
Bang S, Nagata S, Onda M, Kreitman RJ, Pastan I. HA22 (R490A) is a recombinant immunotoxin with increased antitumor activity without an increase in animal toxicity. Clin Cancer Res. 2005;11:1545–1550.
Kreitman RJ, Pastan I. Antibody fusion proteins: anti‐CD22 recombinant immunotoxin moxetumomab pasudotox. Clin Cancer Res. 2011;17:6398–6405.
Aymé G, Adam F, Legendre P, Bazaa A, Proulle V, Denis CV, et al. A novel single‐domain antibody against von Willebrand factor A1 domain resolves leukocyte recruitment and vascular leakage during inflammation—brief report. Arterioscler Thromb Vasc Biol. 2017;37:1736–1740.
Drakeford C, O'Donnell JS. Targeting von Willebrand factor‐mediated inflammation. Am Heart Assoc. 2017;37:1590–1591.
Ulrichts H, Silence K, Schoolmeester A, de Jaegere P, Rossenu S, Roodt J, et al. Antithrombotic drug candidate ALX‐0081 shows superior preclinical efficacy and safety compared with currently marketed antiplatelet drugs. Blood. 2011;118:757–765.
EMA. Cablivi. 2018. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/cablivi. Accessed 3 Oct 2023.
Musiał‐Kopiejka M, Polanowska K, Dobrowolski D, Krysik K, Wylęgała E, Grabarek BO, et al. The effectiveness of brolucizumab and aflibercept in patients with neovascular age‐related macular degeneration. Int J Environ Res Public Health. 2022;19:2303.
Rashid MH. Full‐length recombinant antibodies from Escherichia coli: production, characterization, effector function (Fc) engineering, and clinical evaluation. MAbs. 2022;14:2111748.
Bhatt DL, Pollack CV, Weitz JI, Jennings LK, Xu S, Arnold SE, et al. Antibody‐based ticagrelor reversal agent in healthy volunteers. N Engl J Med. 2019;380:1825–1833.
Kathman SJ, Wheeler JJ, Bhatt DL, Arnold SE, Lee JS. Population pharmacokinetic–pharmacodynamic modeling of PB2452, a monoclonal antibody fragment being developed as a ticagrelor reversal agent, in healthy volunteers. CPT: Pharmacomet Syst Pharmacol. 2022;11:68–81.
Bhatt DL, Pollack CV, Mazer CD, Angiolillo DJ, Steg PG, James SK, et al. Bentracimab for ticagrelor reversal in patients undergoing urgent surgery. NEJM Evidence. 2022;1:EVIDoa2100047.
Damato BE, Dukes J, Goodall H, Carvajal RD. Tebentafusp: T cell redirection for the treatment of metastatic uveal melanoma. Cancers. 2019;11:971.
Liddy N, Bossi G, Adams KJ, Lissina A, Mahon TM, Hassan NJ, et al. Monoclonal TCR‐redirected tumor cell killing. Nat Med. 2012;18:980–987.
Brown J, Rasamoelisolo M, Spearman M, Bosc D, Cizeau J, Entwistle J, et al. Preclinical assessment of an anti‐EpCAM immunotoxin: locoregional delivery provides a safer alternative to systemic administration. Cancer Biother Radiopharm. 2009;24:477–487.
Di Paolo C, Willuda J, Kubetzko S, Lauffer I, Tschudi D, Waibel R, et al. A recombinant immunotoxin derived from a humanized epithelial cell adhesion molecule‐specific single‐chain antibody fragment has potent and selective antitumor activity. Clin Cancer Res. 2003;9:2837–2848.
Premsukh A, Lavoie JM, Cizeau J, Entwistle J, MacDonald GC Development of a GMP phase III purification process for VB4‐845, an immunotoxin expressed in E. coli using high cell density fermentation. Protein Expression Purif. 2011;78:27–37.
Piedmonte DM, Treuheit MJ. Formulation of Neulasta® (pegfilgrastim). Adv Drug Deliv Rev. 2008;60:50–58.
FDA. STIMUFEND® (pegfilgrastim‐fpgk) injection, for subcutaneous use. 2022. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761173s000lbl.pdf. Accessed 3 Oct 2023.
EMA. Stimufend. 2022. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/stimufend. Accessed 3 Oct 2023.
FDA. Kineret® (anakinra) for injection, for subcutaneous use. 2001. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/103950s5136lbl.pdf. Accessed 3 Oct 2023.
Jen EY, Gao X, Li L, Zhuang L, Simpson NE, Aryal B, et al. FDA approval summary: tagraxofusperzs for treatment of blastic plasmacytoid dendritic cell neoplasm. Clin Cancer Res. 2020;26:532–536.